Lonza has reported higher revenues and profits for H1 2015, but warned that the strength of the Swiss franc means its Visp facility is still finding it hard to compete.
One quarter after announcing a disappointing book-to-bill ratio, CRO Parexel has now renewed its strategic partnership with GlaxoSmithKline and seen its book-to-bill ratio jump to its highest level since 2012.
Quintiles reported almost 14% growth in revenue, which was largely due to increasing revenue from its Integrated Health Services (IHS), which saw almost 35% quarterly growth.
Cambrex reported a dip in revenues in 2009, citing the timing of orders throughout the year, and warned that smaller clients’ funding difficulties and pricing pressures will continue in 2010.
Revenues from Pall’s biopharmaceuticals division grew in fiscal 2009, excluding foreign currency changes, with the company benefiting from the “thriving market” for vaccines and expanding adoption of single-use systems.
Dutch chemicals and drugs group Akzo Nobel saw its net income
accelerate in the third quarter of this year, to the surprise of
analysts and investors, and helped by cost reductions and a big
gain from the divestment of its coatings...
Instruments specialist Mettler Toledo reports flat sales in a
difficult operating environment for the sector, but says that
investments in R&D should pay off going forward.
Pall has reported a 10 per cent rise in sales to $471 million
(€430m) in the fourth quarter, boosted by currencies and the
recently-acquired FSG operations.
